<div id="readability-page-1"><p>Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) were down 7.2% on Friday after The Goldman Sachs Group lowered their price target on the stock from $22.00 to $17.00. The Goldman Sachs Group currently has a neutral rating on the stock. Kestra Medical Technologies traded as low as $18.05 and last traded at $17.8650. Approximately 82,926 shares changed hands during trading, a decline of 76% from the average daily volume of 346,349 shares. The stock had previously closed at $19.25.</p><p>Other analysts have also issued research reports about the stock. BTIG Research  reiterated a &#34;buy&#34; rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research note on Tuesday. Stifel Nicolaus  set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Friday, December 12th. Piper Sandler boosted their target price on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, December 12th. Wells Fargo &amp; Company boosted their target price on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, December 12th. Finally, Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Kestra Medical Technologies in a research note on Monday, March 23rd. Three analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has issued  a Sell rating to the company's stock. According to data from MarketBeat.com, the company  has an average rating of &#34;Hold&#34; and an average price target of $27.40.</p><p><b>Check Out Our Latest Stock Report on KMTS</b></p><h2>Insider Activity at Kestra Medical Technologies</h2><p>In related news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $20.27, for a total value of $304,050.00. Following the completion of the transaction, the insider owned 364,786 shares in the company, valued at $7,394,212.22. This represents a 3.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 45,000 shares of company stock worth $1,030,050 in the last three months. 3.60% of the stock is currently owned by corporate insiders. </p><h2>Hedge Funds Weigh In On Kestra Medical Technologies</h2><p>Institutional investors and hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC purchased a new stake in shares of  Kestra Medical Technologies during the fourth quarter valued at $31,000.  Russell Investments Group Ltd. raised its holdings in  Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock worth $41,000 after buying an additional 474 shares during the period.  China Universal Asset Management Co. Ltd. purchased a new stake in  Kestra Medical Technologies during the third quarter valued at about $48,000.  BNP Paribas Financial Markets lifted its stake in  Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company's stock valued at $65,000 after buying an additional 1,638 shares in the last quarter.  Finally, Daiwa Securities Group Inc. purchased a new stake in  Kestra Medical Technologies during the fourth quarter valued at about $72,000. </p><h2>Kestra Medical Technologies Stock Down 7.0%</h2><p>The business's 50 day simple moving average is $22.79 and its 200 day simple moving average is $24.48. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.04 billion and a PE ratio of -4.52. </p><p>Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The firm had revenue of $24.55 million during the quarter. Kestra Medical Technologies's revenue for the quarter was up 62.7% on a year-over-year basis. </p><h2>Kestra Medical Technologies Company Profile</h2> (Get Free Report)<p>We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.</p><h2>Read More</h2><ul><li>Five stocks we like better than Kestra Medical Technologies</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Kestra Medical Technologies Right Now?</h2><p>Before you consider Kestra Medical Technologies, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.</p><p>While Kestra Medical Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

KMTS

<p>Shares of Kestra Medical Technologies (NASDAQ:KMTS) fell 7.2% after Goldman Sachs downgraded the stock, lowering its price target from $22.00 to $17.00. The stock traded as low as $18.05, with a significant drop in trading volume. Other analysts have mixed ratings, with BTIG Research maintaining a "buy" rating and a $32.00 target. The company reported a quarterly loss of ($0.61) EPS, missing estimates, despite a 62.7% year-over-year revenue increase. Kestra focuses on wearable medical devices for cardiovascular disease management.</p>

Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Down 7.2% on Analyst Downgrade